ChemoMetec Gross Profit vs. Return On Equity

CHEMM Stock  DKK 480.80  5.00  1.03%   
Based on the measurements of profitability obtained from ChemoMetec's financial statements, ChemoMetec AS may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess ChemoMetec's ability to earn profits and add value for shareholders.
For ChemoMetec profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ChemoMetec to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ChemoMetec AS utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ChemoMetec's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ChemoMetec AS over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between ChemoMetec's value and its price as these two are different measures arrived at by different means. Investors typically determine if ChemoMetec is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ChemoMetec's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ChemoMetec AS Return On Equity vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ChemoMetec's current stock value. Our valuation model uses many indicators to compare ChemoMetec value to that of its competitors to determine the firm's financial worth.
ChemoMetec AS is number one stock in gross profit category among its peers. It also is number one stock in return on equity category among its peers . The ratio of Gross Profit to Return On Equity for ChemoMetec AS is about  790,969,535 . Comparative valuation analysis is a catch-all model that can be used if you cannot value ChemoMetec by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ChemoMetec's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

ChemoMetec Return On Equity vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

ChemoMetec

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
384.25 M
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

ChemoMetec

Return On Equity

 = 

Net Income

Total Equity

 = 
0.49
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

ChemoMetec Return On Equity Comparison

ChemoMetec is currently under evaluation in return on equity category among its peers.

ChemoMetec Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in ChemoMetec, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ChemoMetec will eventually generate negative long term returns. The profitability progress is the general direction of ChemoMetec's change in net profit over the period of time. It can combine multiple indicators of ChemoMetec, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ChemoMetec AS engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company was founded in 1997 and is headquartered in Allerd, Denmark. ChemoMetec operates under Medical Equipment classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 155 people.

ChemoMetec Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on ChemoMetec. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ChemoMetec position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ChemoMetec's important profitability drivers and their relationship over time.

Use ChemoMetec in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ChemoMetec position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoMetec will appreciate offsetting losses from the drop in the long position's value.

ChemoMetec Pair Trading

ChemoMetec AS Pair Trading Analysis

The ability to find closely correlated positions to ChemoMetec could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ChemoMetec when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ChemoMetec - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ChemoMetec AS to buy it.
The correlation of ChemoMetec is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ChemoMetec moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ChemoMetec AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ChemoMetec can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your ChemoMetec position

In addition to having ChemoMetec in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Healthcare Thematic Idea Now

Healthcare
Healthcare Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Healthcare theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in ChemoMetec Stock

To fully project ChemoMetec's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ChemoMetec AS at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ChemoMetec's income statement, its balance sheet, and the statement of cash flows.
Potential ChemoMetec investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although ChemoMetec investors may work on each financial statement separately, they are all related. The changes in ChemoMetec's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ChemoMetec's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.